Valuation: CStone Pharmaceuticals

Market Cap 7.13B 8.34B 1.06B 949M 885M 804M 1.51B 103B 1.53B 10.63B 4.16B 52.3B 3.99B 3.9B 168B P/E 2026 *
-15.4x
P/E 2027 * 4.18x
Enterprise Value 6.15B 7.2B 917M 819M 764M 694M 1.31B 88.8B 1.32B 9.17B 3.59B 45.12B 3.44B 3.37B 145B EV / Sales 2026 *
14.5x
EV / Sales 2027 * 1.8x
Free-Float
79.65%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: CStone Pharmaceuticals

1 day-4.39%
1 week-11.41%
Current month-15.08%
1 month-18.73%
3 months-2.53%
6 months-47.32%
Current year-4.93%
1 week 4.94
Extreme 4.94
5.92
1 month 4.94
Extreme 4.94
6.36
Current year 4.01
Extreme 4.01
10.41
1 year 4.01
Extreme 4.01
10.41
3 years 0.8
Extreme 0.8
13.15
5 years 0.8
Extreme 0.8
13.15
10 years 0.8
Extreme 0.8
19.12
Manager TitleAgeSince
Chief Executive Officer 62 2022-08-24
Director of Finance/CFO - 2023-01-17
Chief Operating Officer 46 2016-07-31
Director TitleAgeSince
Chairman 55 -
Director/Board Member 62 2022-08-24
Director/Board Member 63 2021-07-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/26 Other

Chief Executive Officer

291,500 0.0182%
9/18/26 Other

Chief Executive Officer

72,000 0.0045%
9/17/26 Other

Chief Executive Officer

132,500 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
-4.20%-11.41%-34.85%+175.27% 1.17B
-1.61%+1.72%+38.30%+106.93% 1,060B
-0.76%-0.84%+35.21%+62.70% 623B
+0.39%+4.81%+17.81%+83.77% 480B
-0.29%-0.99%+64.79%+37.06% 352B
-2.03%+1.06%+21.08%+42.16% 345B
-1.92%-0.29%+10.54%+33.20% 274B
-2.36%-1.16%-7.14%+8.68% 249B
-1.37%+0.04%+38.29%+52.33% 223B
+0.17%-0.27%+24.40%+96.82% 182B
Average -1.40%+0.22%+20.84%+69.89% 378.92B
Weighted average by Cap. -1.05%+0.74%+30.40%+68.85%

Financials

2026 *2027 *
Net sales 423M 495M 63.1M 56.35M 52.57M 47.75M 89.86M 6.11B 90.73M 631M 247M 3.11B 237M 232M 9.99B 1.72B 2.02B 257M 229M 214M 194M 366M 24.87B 369M 2.57B 1B 12.64B 964M 943M 40.65B
Net income -384M -449M -57.19M -51.07M -47.65M -43.28M -81.44M -5.54B -82.24M -572M -224M -2.81B -215M -210M -9.05B 680M 796M 101M 90.61M 84.53M 76.79M 144M 9.83B 146M 1.01B 397M 4.99B 381M 373M 16.06B
Net Debt -978M -1.14B -146M -130M -121M -110M -208M -14.12B -210M -1.46B -570M -7.18B -547M -536M -23.08B -4.02B -4.71B -600M -536M -500M -454M -854M -58.1B -863M -6B -2.35B -29.52B -2.25B -2.2B -94.94B
Projected Income Statement - Annual - CStone Pharmaceuticals
Logo CStone Pharmaceuticals
CStone Pharmaceuticals is an investment holding company primarily engaged in research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Employees
147
Date Price Change Volume
26-10-08 HK$5.020 -4.20% 5,814,770
26-10-08 HK$5.240 -9.42% 10,841,500
26-10-07 HK$5.785 -1.11% 1,400,500
26-10-06 HK$5.850 +3.17% 2,786,269
26-10-05 HK$5.670 +0.27% 1,231,500
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Ratings Surperformance© - CStone Pharmaceuticals
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.477CNY
Average target price
12.36CNY
Spread / Average Target
+176.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CStone Pharmaceuticals
  1. Stock Market
  2. Stocks
  3. 2616 Stock